Escherichia coli heat-labile enterotoxin (LT), which causes a characteristic diarrhea in humans and animals, is a strong mucosal immunogen and has powerful mucosal adjuvant activity towards coadministered unrelated antigens. Here we report the different mucosal adjuvanticity of nontoxic LT derivatives, LTS63Y and LT∆110/112, generated by immunizing through two different mucosal routes. Intragastric ( 
Introduction
Heat-labile enterotoxin (LT) produced by enterotoxigenic Escherichia coli (ETEC) and cholera toxin (CT) produced by Vibrio cholerae show 80% homology at the primary amino acid sequence level and have similar 3-D structures (Mekalanos et al., 1983; Sixma et al., 1991; Spangler, 1992) . Both toxins are composed of two functionally distinct domains, the enzymatically active A subunit with ADP-ribosylating activity (Noda et al., 1989; Lycke et al., 1992; Dickinson et al., 1995) , and the pentameric B subunit that contains a G M1 (monosialoganglioside) receptor-binding site (Tsuji et al., 1985; Spiegel, 1990; Bäckström et al., 1997) . The A subunit intoxicates eucaryotic cells by activating Gs, a GTPbinding protein that regulates the levels of second messenger cAMP (Guerrant et al., 1974) . Enhancement of cAMP levels alters ion transport, inducing secretion of water and chloride ions into the small intestine, resulting in traveler's diarrhea or cholera (Spangler, 1992) .
Both CT and LT are strong immunogens by oral and other mucosal routes, via which most antigens are unable to induce immune responses. CT and LT are also known to act as potent mucosal adjuvants and induce immune responses against coadministered non-respondent antigens (Spangler, 1992; Jackson et al., 1993) . However, the highly-toxic nature of these proteins has precluded their clinical use in humans. Attempts have been made to overcome this problem with LT (Lobet et al., 1991; Douce et al., 1995; Di Tommaso et al., 1996; Marchetti et al., 1998) and with CT (Douce et al., 1997; Yamamoto et al., 1997a; Yamamoto et al., 1997b) , using mutagenesis aimed at neutralization of toxicity without compromising immunogenicity. Mutation of amino acids in the NAD binding sites (residues 58-76) or active sites (residues 7, 44, 61, 110 and 112) of the A subunit of cholera toxin resulted in inactivation of the ADP-ribosyltransferase activity and loss of toxicity in Y1 cells (Fontana et al., 1995) . Similar point mutations in the A subunit of E. coli enterotoxin (LTK7, LTK63, LTR72, LTE110D, LTE112D, LTE112K and LTR192G) have produced inactive forms of LT (Tsuji et al., 1990; Lobet et al., 1991; Tsuji et al., 1991; Pizza et al., 1993; Grant et al., 1994; Dickinson et al., 1995; Douce et al., 1995; Giuliani et al., 1998) . However, substitution of Ala to His or Glu at position 72 resulted in a protein with a toxicity indistinguishable from that of wild-type LT, whereas Ala to Arg substitution at the same position greatly reduced toxicity . These observations suggest that mutations at key positions in the active site may affect ribosyltransferase activity, and that the specific amino acid used to replace wild-type residues may affect binding affinities for NAD or substrates. We constructed two novel LT mutants by point mutation of serine at amino acid position 63 to tyrosine (LTS63Y), and double deletion of glutamic acid at positions 110 and 112 (LT∆110/112) (Park et al., 1999) . Modification of these residues, which are located at the putative ADPribosyltransferase active center, has been shown to inactivate ADP-ribosyltransferase activity and enterotoxicity. Here we investigated the mucosal adjuvant properties of the mutant LTs, using H. pylori urease as a coadministered antigen.
Materials and Methods

Mice and immunization
Six-week-old female BALB/c mice were purchased from Charles River (Japan). To test the mucosal adjuvanticity of mutant LTs, mice were immunized either intragastrically with 125 µg of H. pylori urease together with 25 µg of toxin on days 0, 7, 14, and 21, or intranasally with 20 µg of the same antigen coadministered with 2 µg of toxin on days 0, 7, and 14 (Yamamoto et al., 1997a) . For nasal immunization, small volume of antigen suspension was dropped using micropipets. For intragastric immunization, antigen suspension was fed using blunt-ended needle. Fecal extracts and serum samples were collected and monitored for immune responses.
ELISA
Urease-specific antibodies were measured in an enzymelinked immunosorbent assay (ELISA) as described previously (Di Tommaso et al., 1996; Guidry et al., 1997) . Briefly, plates were coated with 1 µg of urease per well, incubated at 37 o C for 1 h, washed three times and blocked for 1 h at 37 o C with 2.5% skim milk in PBS containing 0.05% Tween 20 (PBST). Sera and fecal samples from each mouse were tested using two-fold serial dilutions for the estimation of urease-specific secretory IgA and serum IgG and IgA. Serum or fecal sample (100 µl) was added to each well and incubated for 2 h at 37 o C. After washing six times with PBST, the plates were incubated for 1 h at 37 o C with horseradish peroxidase (HRP)-conjugated anti-mouse antibodies specific for mouse immunoglobulin G (IgG) (1 : 5000), IgA (1: 2000) (KPL) or IgG1, IgG2a or IgG2b (1 : 2000) (Biosource). After washing six times with PBST, bound antibody was visualized by addition of 3,3´,5,5´-tetramethylbenzidine (TMB). The absorbance at 450 nm was determined and ELISA titers were recorded as the highest dilution of serum which gave an absorbance value above the level measured in preimmune samples.
Baterial challenge and assessment of colonization
Helicobacter pylori SS1, a mouse-adapted strain originally isolated from a peptic ulcer patient, was provided by Dr. A. Lee (University of New South Wales, Australia) and was used as the bacterial challenge inoculum (Lee et al., 1997) . The cells were grown as previously described .
Two weeks after the last IN immunization, mice were fed 0.35 M NaHCO 3 to neutralize gastric acidity and then challenged intragastrically with 5 × 10 7 colony-forming units (CFUs) of H. pylori SS1 twice over a two-day period. At day 42 all mice were sacrificed by cervical dislocation. The stomachs were excised, cut along the greater curvature, and rinsed in PBS to remove the stomach contents. The stomach tissues were homogenized with a pellet pestle (Kontes Scientific Glassware) in a 1.5 ml microfuge tube in 0.5 ml of BHI broth. Serial dilutions of the resulting suspension were plated onto blood agar plates and protection levels were assessed by viable counting of the recovered bacteria.
Results
Mucosal adjuvanticity of mutant LTs in IG immunization
We previously showed that both mutant LTs were immunogenic following either IG or IN administration, and that antibody titers induced by IN immunization were slightly higher than those induced by IG immunization (Park et al., 1999) . In the present study, the abilities of mutant LTs to act as mucosal adjuvants were assessed by IG immunization in mice. Groups of mice were immunized intragastrically with 125 µg of H. pylori urease alone or together with 25 µg of wild-type LT, LTS63Y or LT∆110/112. As shown in Figure 1 , mice immunized with H. pylori urease alone showed no significant production of urease-specific antibodies. Mice immunized by coadministration of urease and LT∆110/112 produced strong anti-urease antibody responses, comparable to those observed in mice co-immunized with wild-type LT. In contrast, mice immunized by coadministration of the antigen and LTS63Y showed no significant sero-conversion. Altering the dose of LT∆110/112 to 10 or 125 µg did not cause any change in the immune response to urease. LTS63Y did not show any significant adjuvanticity, even when 125 µg was coadministered with the urease (data not shown). To test the adjuvanticity of LT∆110/112 with other antigens, whole cell lysate (WCL) of H. pylori was used as an antigen and it was observed that LT∆110/112 also induced antibody responses to WCL (data not shown). These data suggest that LT∆− 110/112 effectively functions as a mucosal adjuvant in IG immunization by inducing strong mucosal and systemic antibody responses to coadministered antigens such as H. pylori WCL or urease.
To further assess the immunologic response induced by LT∆110/112 following IG immunization, IgG subclass responses were determined by ELISA. Urease antibody responses enhanced by LT∆110/112 were largely restricted to IgG1 rather than IgG2a or IgG2b subclass in sera, and similar antibody patterns were observed using wild-type LT as an adjuvant ( Figure 3A ). This pattern was not consistent with the immune responses induced by wild-type LT in previous reports, but rather resembled the responses induced by activation of CD4 + Th2-type cells by CT (Munoz et al., 1990; Marinaro et al., 1995; Takahashi et al., 1996; Yamamoto et al., 1997a) .
Mucosal adjuvanticity of mutant LTs in IN immunization
The ability of mutant LTs to function as a mucosal adjuvant was also assessed by IN immunization in mice. IN administration of wild-type LT or LTS63Y demonstrated the capacity of this immunization route to generate powerful mucosal adjuvant responses, as shown in Figure 2 . Groups of mice were immunized intranasally with 20 µg of H. pylori urease alone or coadministered with 2 µg of wild-type LT, LTS63Y or LT∆110/112. Mice immunized intranasally with urease and LTS63Y showed high levels of mucosal and systemic anti-urease responses, including urease-specific secretory IgA, serum IgG and IgA antibodies, which were equivalent to the responses observed when wild-type LT was used as the adjuvant. However, mice immunized by coadministration of urease and LT∆110/112 showed lower levels of antibodies to urease, similar to the levels induced by urease alone. When 0.2 µg of LTS63Y was used, antibody responses to urease in both fecal extracts and sera were lower by a factor of approximately 10, but when 6 µg of LTS63Y was used, no increase in antibody responses to urease was induced. Thus, a 2 µg dose of LTS63Y appeared to be adequate for eliciting adjuvanticity via IN administration.
To further characterize the adjuvant properties of LTS63Y in IN immunization, IgG subclass responses were also analyzed. As shown in Figure 3B , LTS63Y induced IgG1, IgG2a and IgG2b subclass antibody responses to H. pylori urease, which is consistent with a previous report suggesting that antibody response profiles induced by LT are regulated by both CD4 + Th1 and Th2 cell types (Takahashi et al., 1996) . These results were quite different from the IgG subclass response (predominantly IgG1) induced by LT∆110/112 via the IG route ( Figure 3A) .
Colonization of the mouse stomach
The adjuvant activities of LTS63Y and LT∆110/112 were further examined by assessing the protection achieved using H. pylori urease as a vaccine immunogen ( Figure  4 ). The results indicate that H. pylori could not colonize the stomachs of mice immunized intranasally with H. pylori urease coadministered with either mutant or wildtype LT, although a small number of H. pylori cells were detected. The protection against H. pylori challenge was not consistent with level of IgA titers induced by IN immunization with either of mutant LT. It appears that the antibody response to H. pylori urease may not be the only requirement for protection against bacterial challenge, since IN immunization with urease plus LT∆-110/112 as an adjuvant elicited weak antibody responses comparable to those induced by urease alone. This observation is consistent with the demonstration by Ermak et al. (1998) that protection of mice against H. pylori infection by immunization with urease is dependent on MHC class II-restricted, cell-mediated mechanisms .
Discussion
The ability of LT to function as a strong mucosal adjuvant and immunogen has prompted many studies of the mechanisms by which LT induces mucosal immunity, and numerous attempts to eliminate toxicity without impairing adjuvanticity by site-directed mutagenesis of LT. There remains some dispute over the correlation between ADP-ribosyltransferase activity and adjuvanticity. A nontoxic, enzymatically inactive mutant LT (LTE- 112K) was shown to lack adjuvanticity in oral immunization in mice, suggesting that ADP-ribosyltransferase activity may be required for adjuvanticity (Lycke et al., 1992) . However, when delivered via the IN route, the same mutant LTE112K has been shown to exert adjuvant activity (Verweij et al., 1998) . On the other hand, Giuliani et al. (1998) indicated that enzymatic activity is required for full mucosal adjuvanticity by demonstrating that LTR72, which had only 0.6% of wild-type LT enzymatic activity, exhibited a greater mucosal adjuvanticity than the nontoxic, enzymatically inactive mutant LTK63 . Thus, ADP-ribosyltransferase activity may contribute to the adjuvanticity of LT.
In this study, the nontoxic mutants LTS63Y and LT∆110/112 were administered alone or together with H. pylori urease via two immunization routes to assess mucosal adjuvanticity. These mutant LTs were shown to be immunogenic in a previous study and induce high titers of LT-specific antibodies following IG and IN immunization (Park et al., 1999) . In the present study, the mutant LTs showed no ADP-ribosyltransferase activity, but retained adjuvant activity. LTS63Y was an effective mucosal adjuvant when administered intranasally and induced mucosal and systemic antibody responses, while LT∆110/112 was also an effective adjuvant when administered via the IG route. These observations suggest that these mutant LTs enhance the immunogenicity of a coadministered, unrelated protein by a mechanism independent of the ADP-ribosyltransferase activity of wild-type LT. Our results appear to contradict a previous report suggesting that ADP-ribosyltransferase activity is required for adjuvanticity (Lycke et al., 1992) . However, this study involved different LT mutants from ours, and the adjuvant activity of CT or LT may be mediated by two or more different mechanisms, one of which may include intracellular cAMP accumulation following ADPribosylation (Yamamoto et al., 1997a) . Surprisingly, our mutant LTs exhibited different abilities to act as mucosal adjuvants depending on the route of administration. Although the mutant LTs resembled the holotoxin in terms of assembly and cell binding activity, the mutations in the A subunit may influence receptorbinding properties and hence exert different effects on lymphocytes of the mucosal immune system. In contrast to CT, which binds to only G M1 , LT exhibits a broad range of binding affinities including G M1 , G M2 , and asialo-G M1 (Tsuji et al., 1985; Spiegel, 1992; Bäckström et al., 1997) . This suggests that different mutant forms of LT may require different immunization routes for adequate adjuvanticity, and that specific immunization route may elicit specific mechanisms of up-regulation of immune responses, independent of cAMP levels. Thus, selection of the route of immunization may be critical for determining the mucosal adjuvant activity of mutant LTs. Furthermore, in this study, different patterns of antigenspecific IgG subclass responses were induced by different immunization routes, regardless of cAMP levels. LTS63Y as well as wild-type LT induced antigen-specific IgG1, IgG2a and IgG2b responses by IN immunization, indicating that LTS63Y may promote both Th1-and Th2-type responses. This result is consistent with the general pattern of T-cell help induced by LT described by other workers who have studied the cytokines such as INF-γ and IL-5, released by T cells taken from mice following immunization with LT as a mucosal adjuvant (Takahashi et al., 1996) . In contrast, LT∆110/112 as well as wild-type LT induced predominant IgG1 responses following IG immunization, which more closely resembled the Th2-type responses induced by CT (Snapper et al., 1993; Marinaro et al., 1995; Douce et al., 1997) . Kleanthous et al. (1998) showed different IgG1/IgG2a responses following IN, peroral or rectal immunization with recombinant H. pylori urease using wild-type LT as an adjuvant in a Swiss-Webster mouse model. CT has been reported to elicit adjuvanticity by promoting antigen-specific CD4 + Th2-type responses associated with high levels of IL-4 and IL-5 production and provision of help for IgG1 subclass responses (Hörnquist et al., 1993; Yamamoto et al., 1997a) . The mechanism(s) by which these molecules stimulate the mucosal immune responses in different ways has remained largely obscure to date. Different subsets of T helper lymphocytes may be activated by different mucosal immunization routes.
As described above, the choice of administration route may be very important for effective induction of mucosal immune responses. Mucosal vaccines delivered into the nasal tract provide several advantages. For example, lower doses of antigen and adjuvant are required to induce effective antibody responses when compared to IG immunization, which can decrease the cost of vaccination (Partidos et al., 1996; Yamamoto et al., 1997a) . IN immunization effectively induces not only systemic IgG but also secretory IgA responses in mucosal effector tissues. In this study, IN immunization induced higher levels of secretory IgA and systemic IgG and IgA antibodies than IG immunization, despite requiring only 15% of the H. pylori urease and 6% of the adjuvant. In addition, IN immunization may involve less risk of anaphylactic reactions, since the doses used in IN immunization induce lower total and antigen-specific IgE level in serum (Marinaro et al., 1995; Yamamoto et al., 1997a ). The results of our H. pylori challenge experiments demonstrated that immunization of mice with urease together with either mutant LT significantly suppressed H. pylori infection (Figure 4 ). Although IN immunization with H. pylori urease and LTS63Y or LT∆110/112 did not entirely prevent H. pylori colonization of the stomachs of the immunized mice after intragastric challenge, it significantly diminished the colonization levels. Similar protection results were also reported by Kleanthous et al. (1998) with wild-type LT as an adjuvant. Thus, intranasal vaccination using nontoxic mutant LT as an adjuvant may be useful in human disease prevention, although it remains to be determined whether the antibody responses elicited in humans will be sufficient to confer protection.
In conclusion, the mutant LTs in this study retained the high adjuvanticity of native LT but lacked ADP-ribosyltransferase activity and would therefore not be expected to induce diarrhea in humans. These mutant LTs would be suitable for use in any vaccine formulation designed to elicit immunity via mucosal delivery; in particular, LTS63Y functioned as an effective adjuvant when given intranasally, whereas LT∆110/112 showed high adjuvanticity by IG immunization. It is possible that depending on immunization routes, LT, LTS63Y, or LT∆110/112 may activate either Th2-type or balanced Th1/Th2-type responses via induction of specific cytokine profiles. The mutant LTs in this study may retain different biological properties and may be useful tools with which to examine the mechanisms of induction of mucosal adjuvanticity.
